Clinical Trials | November 16, 2025
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Diversifying its portfolio to include late-phase antiviral agent
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
FIBROSARC did not meet its primary PFS endpoint in the final analysi
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Subscribe To Our Newsletter & Stay Updated
